Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial

Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial

Visa andra versioner (1)

<p><strong>Background</strong> Cases of Middle East respiratory syndrome coronavirus (MERS-CoV) infection continue to rise in the Arabian Peninsula 7 years after it was first described in Saudi Arabia. MERS-CoV poses a significant risk to public health security because of an absenc...

Full beskrivning

Bibliografiska uppgifter
Huvudupphovsmän:	Folegatti, PM, Bittaye, M, Flaxman, A, Ramos Lopez, F, Bellamy, D, Mair, C, Makinson, R, Sheridan, J, Boyd, A, Tran, N, Silman, D, Poulton, I, Datoo, M, Marshall, J, Themistocleous, Y, Lawrie, A, Roberts, R, Berrie, E, Lambe, T, Hill, A, Ewer, K, Gilbert, S, Et al.
Materialtyp:	Journal article
Språk:	English
Publicerad:	Elsevier 2020

Liknande verk

Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial
av: Folegatti, PM, et al.
Publicerad: (2020)

Safety and immunogenicity of a replication deficient simian adenoviral vectored chikungunya vaccine: A phase I, first-in-human, dose escalation trial
av: Folegatti, PM, et al.
Publicerad: (2019)

Safety and immunogenicity of adenovirus and poxvirus vectored vaccines against a Mycobacterium avium complex subspecies
av: Folegatti, P, et al.
Publicerad: (2021)

Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine
av: Folegatti, P, et al.
Publicerad: (2019)

A single dose of ChAdOx1 Chik vaccine induces neutralising antibodies against four chikungunya virus lineages in a phase 1 clinical trial
av: Folegatti, P, et al.
Publicerad: (2021)

Safety and Immunogenicity of Adenovirus and Poxvirus Vectored Vaccines against a Mycobacterium Avium Complex Subspecies
av: Pedro M. Folegatti, et al.
Publicerad: (2021-03-01)

Safety and Immunogenicity of the Heterosubtypic Influenza A Vaccine MVA-NP+M1 Manufactured onthe AGE1.CR.pIX Avian Cell Line
av: Folegatti, P, et al.
Publicerad: (2019)

CMV-associated T cell and NK cell terminal differentiation does not impact immunogenicity of ChAdOx1 vaccination
av: Sharpe, HR, et al.
Publicerad: (2022)

Safety and immunogenicity of ChAdOx1 MERS Vaccine Candidate in Healthy Middle Eastern Adults: a dose-escalation, open-label, non-randomised, phase 1b trial
av: Bosaeed, M, et al.
Publicerad: (2021)

A three-antigen Plasmodium falciparum DNA prime—Adenovirus boost malaria vaccine regimen is superior to a two-antigen regimen and protects against controlled human malaria infection in healthy malaria-naïve adults
av: Sklar, MJ, et al.
Publicerad: (2021)

Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine
av: Pedro M. Folegatti, et al.
Publicerad: (2019-05-01)

Deep immune phenotyping and single-cell transcriptomics allow identification of circulating TRM-like cells which correlate with liver-stage immunity and vaccine-induced protection from malaria
av: Noe, A, et al.
Publicerad: (2022)

Safety and Immunogenicity of the Heterosubtypic Influenza A Vaccine MVA-NP+M1 Manufactured on the AGE1.CR.pIX Avian Cell Line
av: Pedro M. Folegatti, et al.
Publicerad: (2019-03-01)

Clinical development of viral vectored vaccines against MERS-COV
av: Ewer, K, et al.
Publicerad: (2018)

Efficacy and safety of a modified Vaccinia Ankara-NP+M1 vaccine combined with QIV in people aged 65 and older: a randomised controlled clinical trial (INVICTUS)
av: Butler, C, et al.
Publicerad: (2021)

CMV-associated T cell and NK cell terminal differentiation does not affect immunogenicity of ChAdOx1 vaccination
av: Hannah R. Sharpe, et al.
Publicerad: (2022-03-01)

A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial
av: Pedro M. Folegatti, et al.
Publicerad: (2021-07-01)

Safety and immunogenicity of varied doses of R21/Matrix-M™ vaccine at three years follow-up: A phase 1b age de-escalation, dose-escalation trial in adults, children, and infants in Kilifi-Kenya [version 1; peer review: 2 approved]
av: Omar Ngoto, et al.
Publicerad: (2023-10-01)

Viral vectors as vaccine platforms: from immunogenicity to impact
av: Ewer (nee Russell), K, et al.
Publicerad: (2016)

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
av: Folegatti, PM, et al.
Publicerad: (2020)

Deep Immune Phenotyping and Single-Cell Transcriptomics Allow Identification of Circulating TRM-Like Cells Which Correlate With Liver-Stage Immunity and Vaccine-Induced Protection From Malaria
av: Andrés Noé, et al.
Publicerad: (2022-02-01)

A Phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS
av: De Barra, E, et al.
Publicerad: (2014)

Prime and target immunization protects against liver-stage malaria in mice
av: Gola, A, et al.
Publicerad: (2018)

Methods for measuring T-cell memory to vaccination: from mouse to man
av: Flaxman, A, et al.
Publicerad: (2018)

Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors.
av: Sheehy, S, et al.
Publicerad: (2012)

Safety and immunogenicity of the novel plasmodium falciparum blood-stage vaccine RH5.1/AS01B in a phase I/IIA clinical trial
av: Minassian, AM, et al.
Publicerad: (2017)

Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African children and infants
av: Bliss, C, et al.
Publicerad: (2016)

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
av: Barrett, J, et al.
Publicerad: (2020)

Efficacy and Safety of a Modified Vaccinia Ankara-NP+M1 Vaccine Combined with QIV in People Aged 65 and Older: A Randomised Controlled Clinical Trial (INVICTUS)
av: Chris Butler, et al.
Publicerad: (2021-08-01)

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
av: Flaxman, A, et al.
Publicerad: (2021)

Safety and immunogenicity of heterologous prime-boost immunization with viral-vectored malaria vaccines adjuvanted with Matrix-M
av: Venkatraman, N, et al.
Publicerad: (2017)

Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1.
av: Berthoud, T, et al.
Publicerad: (2011)

Safety and immunogenicity of the novel plasmodium falciparum blood-stage vaccine chad63-mva rh5 in a phase ia clinical trial
av: Payne, R, et al.
Publicerad: (2017)

Expansion of CD57+KLRG1+ T cells is associated with reduced vaccine responses in CMV+ young adults
av: Bowyer, G, et al.
Publicerad: (2020)

A phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS.
av: Eoghan de Barra, et al.
Publicerad: (2014-01-01)

High level efficacy in humans of a next-generation plasmodium falciparum anti-sporozoite vaccine: R21 in Matrix-M (TM) adjuvant
av: Venkatraman, N, et al.
Publicerad: (2017)

Real de-escalation or escalation in disguise?
av: Maggie Banys-Paluchowski, et al.
Publicerad: (2023-06-01)

Safety and immunogenicity of malaria vectored vaccines given with routine EPI vaccines in Gambian infants and neonates: a randomized controlled trial
av: Mensah, V, et al.
Publicerad: (2017)

Vaccines against Ebola virus
av: Venkatraman, N, et al.
Publicerad: (2017)

Methods for Measuring T-Cell Memory to Vaccination: From Mouse to Man
av: Amy Flaxman, et al.
Publicerad: (2018-07-01)